Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors

Next Previous
X
Search
Trial Profile

Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 23 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BMS-986277 (Primary) ; Nivolumab (Primary)
  • Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Glandular and epithelial neoplasms; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 23 Dec 2020 Status changed from active, no longer recruiting to discontinued as business objectives have changed.
    • 11 Jul 2019 Status changed from recruiting to active, no longer recruiting.
    • 18 Jul 2018 Planned number of patients changed from 146 to 200.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top